The Biotech Industry and Clinical Trials in Israel

The Biotech Industry and Clinical Trials in Israel

Loading
Loading Social Plug-ins...
Language: English
Save to myLibrary Download PDF
Go to Page # Page of 25

Description: Topics discussed include; how each healthcare dollar is spent, Global pharmaceutical sales from 2001-2008, Biopharmaceutical Companiesí investment in R&D. Also discussed is the current state of drug development research, personalized medicine, and Israelís Life Science Industry.

 
Author: Zeev Zelig (Fellow) | Visits: 1803 | Page Views: 1812
Domain:  Medicine Category: Biotech/Pharma 
Upload Date:
Short URL: https://www.wesrch.com/medical/pdfME1XXF000ZQMN
Loading
Loading...



px *        px *

* Default width and height in pixels. Change it to your required dimensions.

 
Contents:
How Each Health Care Dollar Is Spent
Home Health Nursing & Home Care 8% Administrative & Net Costs 7% Rx Drugs 10%

Physicians & Clinical Services 21%

Hospital Care 31%

Other 23%

Source: Centers for Medicare & Medicaid Services, "National Health Expenditures," 7 January 2008, http://www.cms.hhs.gov/NationalHealthExpendData.

Biopharmaceutical Companies' Investment in R&D Increasing Steadily
In 2008, total industry spending on R&D was $65.2 billion

$70

Expenditures (Billions of Dollars)

$60

PhRMA Member Companies' R&D Expenditures Entire Biopharma Industry

$63.2 $56.1 $47.9

$65.2

$51.8 $50 $47.6 $43.4 $39.9 $37.0

$50.3

$40 $29.8 $26.0 $22.7 $21.0 $31.0

$34.5

$30 $16.9 $19.0

$20

$15.2

$10

$0

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 (est)
Source: Burrill & Company, analysis for PhRMA, 2005-2009; Pharmaceutical Research and Manufacturers of America, PhRMA Annual Member Survey (Washington, DC: PhRMA, 1981�2009).

Pharmaceuticals �Timing and Numbers
�For each 1000 candidates tested one will reach a clinical trial �On average 6 years to trial �10,000 clinical trials conducted annually �Full trials can take 8 years �Cost of development may be $800M �Generic cost 10-25% branded price

Current state of drug development research.

Personalized medicine.

�Many more clinical trails �Very limited number of patients �Long recruitment time �Very expensive

An Attractiveness Scale for Country Evaluation.

A.T. Kearney, Fishing for Opportunities. Pharmaceutical Executive, Jun 1, 2006

A.T. Kearney, Fishing for Opportunities. Pharmaceutical Executive, Jun 1, 2006

Israel Life Science Industry : A platform for excellence.
� Strong Entrepreneurial Spirit. � Improvisation � Risk taking attitude. � Military service based � Intense social networking.
� Convergence � Different socio-economy background � Informality � Easy access to decision makers.

� Extensive new immigrants � Multicultural environment

Israel Life Science Industry : A platform for excellence.
1. Technology Transfer Organizations 2. Commercialized defense technology 3. Healthcare system 4. Strong entrepreneurial spirit 5. Powerful VC community 6. Highly skilled workforce 7. Institutional incentives

Israel Life Science Industry : A platform for excellence.
Over 900 Companies
AgroBio, 4% Biotechnology, 16% Others 1% Pharm aceuticals 16% Medical Devices, 56%

Healthcare IT 6%

Israel Life Science Industry : A platform for excellence.
Highly Skilled Workforce
34% of the population holds university degrees. 24% of the working force work in the Life Sciences (3rd after the US and Holland). 12% hold advanced degree 40% of the 90's immigrants hold academic degree No .Engineers & Scientists per capita

What criteria do pharmaceutical companies consider when deciding where to hold studies?

Decision Criteria:

� Ability to run complexed protocol � Availability of patients � Predictable recruitment cycle � Rapid recruitment � Timelines for approvals

Decision Criteria:

� Sites with trained personnel � Availability of state of the art lab and medical equipment � Scientific credibility � Populations of interest � Costs

Decision Criteria:

� Availibility of registries � Quality of investigators � First line KOLs � Size of potential market

Decision Criteria:

� Intellectual property rights protection � Environment for innovative products

Clinical Trails in Israel (INS -Yearly)

19

Number of CT in Israel

Medical Devices 20

CT with no drugs

CT with drugs
2008 not final

Clinical Trials in Israel 2008 � by Hospital

2008 NIS (m) 2008 total no.

21

Clinical Trials : Win-Win Formula

The Public

The Patients

Academia

The Israeli Economy

Clinicians & Scientists

The Health Services

WIN � WIN

WIN � WIN

� The Patient � The Physician � The Medical Institute � The State

How can the State help ?

Choose Israel

Let us do the rest !

Subscribe
x